Complicated Urinary Tract Infections
Sep 28, 2026
New Antimicrobial Approvals and the Fight Against Drug-Resistant Infections
Summary After years of a stalled pipeline, 2026 brought two major FDA antibiotic approvals, GSK/Spero Therapeutics’ UTEBZI (tebipenem pivoxil) and Wockhardt’s ZAYNICH (cefepime and zidebactam), signaling real progress against drug-resistant infections. Resistant bacteria are turning routine infections into m...
Read More...
Jan 23, 2024
BMS, and Exelixis’s Opdivo + CABOMETYX in First-Line Advanced Renal Cell Carcinoma; AIRSUPRA Now Available as the First and Only FDA-approved Anti-inflammatory Rescue Option for Asthma; AstraZeneca’s Voydeya Receives First-ever Regulatory Approval; EMA Grants ODD to GC Biopharma’s Sanfilippo Syndrome (Type A) Treatment; FDA Approves NRx Pharma’s IND Application of NRX-101; FDA Fast Track Designation to Kyverna’s KYV-101
Opdivo in Combination with CABOMETYX Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Bristol Myers Squibb and Exelixis, Inc. have released the four-year follow-up findings from the CheckMate -9ER trial, which investiga...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
